Global Cell Cryopreservation Market Assessment, By Product [Consumables, Cell Freezing Media, Equipment], By Application [Stem Cells, Oocytes and Embryotic Cells, Sperm Cells, Hepatocytes, Others], By End-user [Biopharmaceutical and Pharmaceutical Companies, Research Institutes, Biobanks, IVF Clinics, Others], By Region, Opportunities and Forecast, 2018-2032F

Global cell cryopreservation market is projected to witness a CAGR of 21.0% during the forecast period 2025-2032, growing from USD 11.19 billion in 2024 to USD 50.88 billion in 2032. The market’s growth is supported by the increasing utilization of cell therapies in various diseases, rising requirements for biobanks, increasing requirements from IVF clinics, growing efforts to preserve biological specimens for longer periods, and rising efforts of the key players of the market to introduce technologically advanced equipment.

Additionally, the rising efforts of different governments to promote stem cells, organs, and blood donations among different ethnicities are also boosting the growth of the cell cryopreservation market. In 2023, fifty organizations and community groups across Wales and England received a share from funding of approximately USD 890,000 (£685,000) as part of the government’s efforts to tackle health inequalities among Asian and Black communities. Previously known as the Community Investment Scheme, the Community Grants Program is managed by the National Health Service Blood and Transplant (NHSBT) and aids in funding community organizations to deliver projects that encourage more Asian and Black individuals to become donors.

Report Attribute	Details
Base Year of the Analysis	2024
Historical Period	2018-2023
Forecast Period	2025-2032
Projected Growth Rate	CAGR of 21.0% between 2025 and 2032
Revenue Forecast in 2032	USD 50.88 billion

Furthermore, the rising efforts of leading companies to augment the availability of novel and advanced products and technologies are also positively influencing the expansion of the global cell cryopreservation market. In September 2024, Colder Products Company (CPC), a part of the Dover Corporation, announced the launch of a novel aseptic micro-connector that has the ability to fit directly into the freeze cassettes used in gene and cell therapy processing. Cryopreservation aids in minimizing material loss of function during storage and product shipment, which occurs prior to therapies being delivered to patients. The company’s MicroCNX ULT connectors provide an efficient and simple method for the sterile connection of tubing and are also compatible with harsh chemicals. Such launches are expected to aid in creating sterile connections outside the biosafety cabinets, allowing for easy transport of biological specimens.

Market leaders, including Merck KGaA, Thermo Fisher Scientific Inc., and Lonza Ltd. have established themselves in the field of cryopreservation technologies and innovative product offerings. These companies heavily invest in bio-preservation research, ensuring continuous innovation in cryopreservation media, freezing techniques, and automation, and focus on developing strategic partnerships and collaborations with biotech companies, research institutions, and biobanks to develop cutting-edge cryopreservation solutions. These companies also focus on investing in research and development activities to introduce novel protocols and technologies to tackle the different challenges faced by the cryopreservation industry.

Increasing Incidences of Infertility Drive Market Growth

The rise in the number of cases of infertility due to the increasing number of medical conditions that affect reproductive health and lifestyle changes are propelling the requirement for various fertility preservation technologies and procedures, propelling the market’s demand. As more couples rely on fertility preservation technologies for parenthood, the requirement for cryopreservation equipment and consumables is rising to store sperm and embryos. Additionally, technological advancements in freezing and vitrification methods are allowing professionals to improve the viability and survival rates of preserved reproductive cells, ensuring successful outcomes. 

The Institute for Health Metrics and Evaluation (IHME) estimates that, by 2050, over three quarters of countries will not have high enough fertility rates to sustain the size of the population over time. Thus, the reliance on fertility preservation technologies is expected to increase in the coming years, providing lucrative growth opportunities for the market.

Favorable Government Policies and Initiatives Support Market Expansion

Introduction of different policies and regulations that protect the privacy of the patients are further bolstering the market’s expansion as the patient population feels more secure is availing different reproductive treatments. In the United States, the Health Insurance Portability and Accountability Act (HIPAA) plays a crucial role in protecting the privacy and security of reproductive health information, particularly in the context of fertility preservation. The new HIPAA regulations, effective June 25, 2024, establish stricter privacy protections for protected health information (PHI) related to reproductive health care. In Europe and the United Kingdom, the GDPR views genetic data as sensitive data or “special categories of personal data,” making their processing for research applications subject to the adoption of technical and organizational safeguards, such as pseudonymization.

Additionally, policies also affect international collaborations in genetic research and cryopreservation as some countries impose restrictions on sharing genetic data across borders due to privacy concerns, impacting the cryopreservation industry. Political decisions influence whether cryopreservation services are covered under employer-sponsored health plans, some governments encourage companies to include such benefits in corporate health policies to boost the growth of the population.

Increasing Construction of Biobanks Boosts Market Demand

The rapid expansion of disease prevention research and increasing requirement for targeted therapies and precision medicine are propelling the requirement for biobanks. Various governments also provide funding and donations to biobanks to support and promote research activities across various domains. In February 2024, the UK government provided an additional USD 27 million (£21 million) for the USD 97 million (£75 million) UK Biobank Limited in Manchester.

Additionally, various integrated healthcare providers are also investing in the construction of biobank facilities in different regions across the globe. In May 2024, CIC Innovation Services LLC and CHA Medical & Bio Group signed a memorandum of understanding for establishing an open innovation center focusing on innovation and research around the Cell Gene Biobank (CGB). Both companies agreed to collaborate to create a biotech-focused innovation ecosystem for supporting and attracting biotech companies and related ventures to CGB, which is being constructed by the CHA Medical & Bio Group in Pangyo, South Korea. Such activities are expected to boost the growth of the research sector and positively influence the expansion of the global cell cryopreservation market.

Technological Advancements Support Market Expansion

The growing efforts by various biotech companies to bolster the development and availability of novel cell cryopreservation technologies to increase convenience and redefine standards for cryopreservation are boosting the global cell cryopreservation market growth. In October 2024, Nucleus Biologics, one of the leading providers of bioprocessing and cell culture solutions for the gene and cell therapy sector, launched NB-KUL DF, a chemically defined, DMSO-free cryomedia set to redefine the standards of cryopreservation. NB-KUL DF outperforms other DMSO-free options in cell expansion, viability, and recovery. Additionally, NB-KUL DF eliminates the issues associated with DMSO-based media, such as the requirement for complex wash steps, patient issues, and additional variability and costs. Such launches mark a new era for cell cryopreservation for therapies and showcase the biotech companies' efforts to create products that make therapies more accessible and consistent for patients.

Additionally, various biotech companies are entering into collaborations and partnerships with others to accelerate the development of novel products and technologies. In October 2023, Cryoport, Inc. and NMDP BioTherapies (formerly known as Be The Match BioTherapies) announced a partnership to expand the former’s capabilities and provide global cryopreservation and bioprocessing support across Europe and the United States. 

IVF Clinics Hold Significant Market Share

The rising cases of infertility and the increasing requirement for the freezing and donating of biological material are propelling the segment’s expansion and bolstering the global cell cryopreservation market size. As per the estimates of the World Health Organization (WHO), 1 in 6 adults across the globe experience infertility in their lifetime. Thus, propelling the requirement for effective and dependable cryopreservation solutions to ensure the viability of frozen eggs and sperm for long periods of time. Additionally, the rising cases of infertility are also augmenting the construction of fertility clinics in various regions across the globe, providing lucrative growth opportunities to the market. In June 2024, a new state-of-the-art fertility clinic was opened in Walnut Creek, United States, to address the rising requirement for expert fertility care. The increasing acceptance and awareness of assisted reproductive technologies (ART) is also boosting the demand for cell cryopreservation tools by IVF clinics. Various government and non-government organizations (NGOs) are also working on raising awareness about infertility, destigmatizing ARTs, and promoting education and understanding.

North America Holds Major Market Share

The expansion of the North American cell cryopreservation market is driven by the increasing emphasis on research and development activities, rising investments in the biotech sector, and the presence of advanced healthcare infrastructure. Additionally, the strong presence of leading market players in the region also provides lucrative growth opportunities for the market by ensuring the availability of advanced and novel technologies. The increased product demand can also be attributed to the rising construction of biobanks in countries such as the United States to support medical research for developing new and personalized therapies.

Furthermore, the rising efforts of various companies and research organizations to expedite cell and gene therapy development and manufacturing are also propelling the market’s demand. In June 2023, GenScript Biotech Corporation and Comprehensive Cell Solutions, a business unit of New York Blood Center, Inc., announced their partnership to spearhead the development of gene and cell therapies to offer seamless and unique solutions that span apheresis and cell collections through cryopreservation of final therapeutics. The partnership will also focus on aiding drug developers in advancing treatment options for immune disorders and blood cancer. Additionally, the increasing breakthroughs in the region in gene and cell therapies are further augmenting the demand for reliable cryopreservation equipment to support clinical trials, distribution, and manufacturing activities.

Future Market Scenario (2025-2032F)

As per the global cell cryopreservation market analysis, the increasing investments in biobanking, advancements in cryoprotectant formulations, and automated cryopreservation systems are expected to provide lucrative growth opportunities to the market. Private organizations and governments across the globe are significantly investing in establishing biobanks to support drug discovery and disease research. Such initiatives are anticipated to boost the market’s growth as biobanking facilities rely on effective cryopreservation technologies for storing biological specimens and ensuring they remain viable for future use. The growing popularity of personalized medicines is also expected to bolster the demand for efficient cell storage solutions, propelling the global cell cryopreservation market demand.

Moreover, the growing focus on cell-based therapies for treating autoimmune diseases, neurological disorders, and cancer, among others, is also expected to bolster the requirement for cell cryopreservation products. According to the estimates of the World Health Organization (WHO), over 35 million new cases of cancer are expected to occur in 2050. Additionally, the market is also expected to benefit from the increasing initiatives that aim to improve the regulatory framework, allowing companies to bring novel products to the market with ease.

Download Free Sample Report

Impact of the U.S. Tariffs on Global Cell Cryopreservation Market

The tariffs are elevating the manufacturing expenses for cryopreservation equipment, including freezers, incubators, and liquid nitrogen supply tanks. These elevations are particularly challenging for small and medium sized clinical facilities, biobanks, and laboratories that are heavily reliant on such equipment. Additionally, the tariffs are also expected to cause significant disruptions in the supply chain as manufacturers may face significant challenges while sourcing different components, resulting in increased costs and delays. Furthermore, the need to relocate manufacturing locations and find alternative suppliers can further introduce operational complexities and increase expenses for medical device companies.

Report Scope

“Cell Cryopreservation Market Assessment, Opportunities and Forecast, 2018-2032F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global cell cryopreservation market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Segments Covered	Product, Application, End-user
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profile	Merck & Co., Inc., Thermo Fisher Scientific Inc., Lonza Group Ltd., GE HealthCare Technologies Inc., BioLife Solutions Inc., Sartorius AG, STEMCELL Technologies Canada Inc., Artivion, Inc, Takara Bio Inc., Corning Incorporated
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, global cell cryopreservation market has been segmented into the following categories: 

• By Product
  • Consumables
    • Cryogenic Vials
    • Cryogenic Tubes
    • Cooler Boxes/Containers
    • Others
  • Cell Freezing Media
    • Ethylene Glycol
    • Dimethyl Sulfoxide
    • Glycerol
    • Others
  • Equipment
    • Freezers
    • Incubators
    • Liquid Nitrogen Supply Tanks
  • By Application
    • Stem Cells
    • Oocytes and Embryotic Cells
    • Sperm Cells
    • Hepatocytes
    • Others
  • By End-user
    • Biopharmaceutical and Pharmaceutical Companies
    • Research Institutes
    • Biobanks
    • IVF Clinics
    • Others
  • By Region
    • North America
    • Europe
    • Asia-Pacific
    • South America
    • Middle East and Africa

Key Players Landscape and Outlook

The rising efforts by the key market players towards novel product launches are providing lucrative growth opportunities for the market. In June 2023, BioLife Solutions Inc, one of the leading suppliers and developers of class-defining bioproduction services and products for gene and cell therapy, announced the launch of their new, large-capacity controlled-rate freezer (CRF). The IntelliRate i67C tabletop freezer fulfills the growing customer requirement for high production of cell therapies. The new CRF has been designed to increase single-batch, LN2 CRF capacity from commercial manufacturing volumes to late- and mid-stage clinical research. Additionally, in October 2024, Cryoport, Inc. announced the launch of their IntegriCell cryopreservation solution provided by Cryoport Systems, along with the opening of their new facility in Texas, United States. The new facility is developed for standardized cryopreservation of leukapheresis material to support the commercialization and development of cell-based therapies. IntegriCell is designed to enhance cell therapy manufacturing efficiency and ensure quality, safety, and product stability to support the development of lifesaving treatment. Such developments and investments are expected to aid the key players in expanding their market share while positively influencing the expansion of the cell cryopreservation market.

Key Players Operating in Global Cell Cryopreservation Market are:

• Merck & Co., Inc.
• Thermo Fisher Scientific Inc.
• Lonza Group Ltd. 
• GE HealthCare Technologies Inc. 
• BioLife Solutions Inc.
• Sartorius AG
• STEMCELL Technologies Canada Inc.
• Artivion, Inc
• Takara Bio Inc.
• Corning Incorporated

If you can't find what you're searching for or have any custom requirements for global cell cryopreservation market, you may approach our team at info@marketsandata.com.